A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Elritercept (KER-050) for Transfusion-Dependent Anemia in Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (RENEW)
September 11, 2026
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)